medric medric
[닫기]
잠시만 기다려 주세요. 로딩중입니다.

암 환자에서의 임상시험용 의약품 처방 오류 분석

Analysis of Prescribing Errors of Investigational Drugs in Oncology Clinical Trials

병원약사회지 2019년 36권 3호 p.366 ~ 373
문진영 ( Moon Jin-Young ) - 이화여자대학교 약학대학

이연홍 ( Lee Yeon-Hong ) - 국립암센터 약제부
이미형 ( Lee Mi-Hyung ) - 국립암센터 약제부
김영주 ( Kim Young-Joo ) - 국립암센터 약제과
곽혜선 ( Kwak Hye-Seon ) - 이화여자대학교 약학대학

Abstract


Objective : Investigational drugs are often considered to be high-risk or hazardous medications. It is necessary to study medication errors in clinical trials. This study aimed at identifying the frequency and types of prescribing errors in oncology clinical trials.

Methods : We retrospectively analyzed investigational drug orders and pharmacist intervention records from December 2015 to February 2017 in the National Cancer Center.

Results : Among 12,387 investigational drug orders, 673 (5.43%) prescribing errors were detected by pharmacists.
Regarding the route of administration, the prescription error rate related to IV medications was higher than that of oral medications (7.23% vs. 4.34%). The most common prescribing error in IV medications were wrong medication kit number (164 cases, 48.52 %) followed by incorrect diluent (75 cases, 22.19%), wrong dose (70 cases, 20.71%), and omission of information (20 cases, 5.92%). Meanwhile, the most common prescribing error in oral medications were wrong medication kit number (119 cases, 35.52 %) followed by incorrect quantity (67 cases, 20.0%), wrong dose (58 cases, 17.31%), and incorrect treatment duration (45 cases, 13.43%).

Conclusions : This study provides the frequency and types of prescribing errors in oncology clinical trials. The pharmacist intervention may improve safety of investigational drug use.

키워드

Pharmacist intervention; Prescribing error; Clinical trial
원문 및 링크아웃 정보
 
등재저널 정보
KCI